The Committee for Medical and Pharmaceutical Control in Kazakhstan has officially rescinded the registration status of two distinct medications. According to formal orders signed on October 1, 2026, by the acting chair of the committee, the affected drugs are Sandostatin and Iodobalance. Sandostatin, provided in various concentrations for injection, is utilized for managing acromegaly and specific neuroendocrine tumors. Meanwhile, Iodobalance, which consists of 200 mcg potassium iodide tablets, is primarily prescribed for the prevention and treatment of iodine deficiency. These regulatory actions effectively remove the authorization for these specific products to be distributed or sold within the country. The decision follows a review process by the national health authorities, though the specific underlying reasons for the withdrawal were not fully detailed in the initial announcement.
Source : Tengrinews
Photo : Tengrinews
